Capricor shares fall 11% as November FDA decision nears
Capricor Therapeutics shares fell 11% Wednesday, extending weeks of declines as investors weighed the odds of FDA approval for its lead therapy, Deramiocel. The FDA is slated to decide in November.
Capricor Therapeutics (CAPR) shares dropped 11% on Wednesday, extending a decline that has lasted weeks, as investors assessed the likelihood that the U.S. Food and Drug Administration will approve the company’s lead therapy, Deramiocel. The FDA is scheduled to decide whether to approve the drug to treat Duchenne…